TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21923601
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol sulfate 2.5 mg diluted in 3 ml of normal saline
Study: 21923601
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 ml of normal saline)
Study: 18326600
Drug: MCT oil
Normalized name: Organic MCT Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCT oil (18-24 g/d)
Study: 16507194
Drug: Combined anaesthesia
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined anaesthesia group (1 mL kg‐1 of caudal-epidural bupivacaine 0.25%)
Study: 16507194
Drug: Balanced anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced anaesthesia group (5 microg kg‐1 of intravenous fentanyl)
Study: 11007389
Drug: Textured silicone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Textured silicone gel implants
Study: 11007389
Drug: Smooth silicone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smooth silicone gel implants
Study: 8686202
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (0.6-0.7 g/kg/day) and enalapril (2-10 mg/day)
Study: 8263317
Drug: Paroxetine 20-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20-30 mg
Study: 30358715
Drug: 25‐mug 17beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25‐mug 17beta‐estradiol vaginal tablets (Vagifem)
Study: 30358715
Drug: 1.25‐mg conjugated
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25‐mg conjugated equine estrogen vaginal cream (Premarin Vaginal Cream)
Study: 22409735
Drug: Four weekly
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four weekly multiprofessional senior group meetings with one follow-up home visit
Study: 18602429
Drug: High LC
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High LC n-3 FA (>1300 mg/day)
Study: 18602429
Drug: Low LC
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low LC n-3 FA (<260 mg/day)
Study: 10520385
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia (PCA) with morphine intravenously by a PCA Plus Micro Delivery Device for at least 48 hours
Study: 10520385
Drug: Nurse-administered intravenous
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-administered intravenous morphine followed by oral acetaminophen with or without codeine in 24 to 36 hours
Study: 1935862
Drug: Sandocal containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandocal containing 1 g of effervescent calcium
Study: 1935862
Drug: Calsup containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calsup containing 1 g of calcium as the carbonate
Study: 1935862
Drug: Caltrate containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caltrate containing 1.2 g of calcium as the carbonate
Study: 7042111
Drug: Acebutolol 200
Normalized name: acebutolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol 200 mg thrice daily
Study: 7042111
Drug: Acebutolol 400
Normalized name: acebutolol 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol 400 mg thrice daily
Study: 30053956
Drug: Fluticasone furoate/vilanterol
Normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/vilanterol (FF/VI; 100/25 or 200/25 μg)
Study: 30053956
Drug: Twice-daily inhaled
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily inhaled corticosteroids/long-acting β2-agonists (ICS/LABA)
Study: 25274615
Drug: Bevacizumab 5
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 5 mg/kg with WBRT (30 Gy/15 fractions/3 weeks)
Study: 25274615
Drug: Bevacizumab 10
Normalized name: bevacizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 10 mg/kg with WBRT (30 Gy/15 fractions/3 weeks)
Study: 25274615
Drug: Bevacizumab 15
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 15 mg/kg with WBRT (30 Gy/10 fractions/2 weeks)
Study: 25274615
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (Bevacizumab combined with WBRT)
Study: 19647405
Drug: Noninvasive coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noninvasive coronary flow reserve (CFR) assessment using intravenous adenosine infusion
Study: 17284138
Drug: Intramuscular aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intramuscular aripiprazole 5.25 mg
Study: 17284138
Drug: Intramuscular aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intramuscular aripiprazole 15 mg
Study: 17284138
Drug: Intramuscular haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular haloperidol 7.5 mg
Study: 12571942
Drug: New fumanling
Approvals — FDA: no, EMA: no, PMDA: no
Description: New fumanling cream
Study: 3065158
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous insulin infusion (CSII) (n = 48)
Study: 3065158
Drug: Intensified conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified conventional treatment (ICT) (n = 41)
Study: 3065158
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (CT) (n = 28)
Study: 23663752
Drug: All apremilast
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All apremilast doses
Study: 19192663
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus CIK cell transfusion
Study: 12958052
Drug: Physostigmine (PHYS)
DrugBank: Physostigmine (DB00981)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine (PHYS) 0.12 microg/minute/kg, 7-hour infusion
Study: 9417492
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no selenium treatment)
Study: 30219886
Drug: 1-year trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1-year trastuzumab plus chemotherapy (arm A, long)
Study: 30219886
Drug: 9 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 9 weeks trastuzumab plus chemotherapy (arm B, short)
Study: 26369284
Drug: Rapid advancement
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid advancement (36 ml/kg/day)
Study: 26369284
Drug: High initiation
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High initiation (24 ml/kg/day)
Study: 26369284
Drug: Low initiation
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low initiation (4 ml/kg/day)
Study: 26369284
Drug: Low advancement
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low advancement (24 ml/kg/day)
Study: 26369284
Drug: High advancement
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High advancement (36 ml/kg/day)
Study: 24585432
Drug: YSP Amoxicillin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: YSP Amoxicillin® capsule
Study: 22909146
Drug: Oxybutynin chloride
Normalized name: Oxybutynin Chloride
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxybutynin chloride topical gel (OTG) 10% applied once daily (1g, 100mg oxybutynin)
Study: 22909146
Drug: Immediate-release oxybutynin
Normalized name: oxybutynin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release oxybutynin (OXB-IR) 5mg capsule three times/day
Study: 20575621
Drug: Diclofenac epolamine
Normalized name: Diclofenac Epolamine
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac epolamine 1.3% topical patch (DETP) applied once daily for 7 days
Study: 15138297
Drug: FTY720 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTY720 1 mg alone
Study: 15138297
Drug: Cyclosporine 200
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine 200 mg twice daily
Study: 15138297
Drug: FTY720 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTY720 1 mg with cyclosporine
Study: 11585480
Drug: Weekly administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly administration of antenatal corticosteroids (betamethasone, 12 mg intramuscularly repeated once in 24 hours for 2 doses every week until 34 weeks' gestation or delivery)
Study: 11585480
Drug: Single course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single course of antenatal corticosteroids (either betamethasone, 12 mg intramuscularly repeated once in 24 hours for 2 doses, or dexamethasone, 6 mg intramuscularly repeated every 12 hours for 4 doses)
Study: 855849
Drug: Fat excretion
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat excretion
Study: 30707361
Drug: Repeat Botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat Botulinum toxin 100 U injections
Study: 24226381
Drug: Tropisetron as
Normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron as a single medication (Group IV)
Study: 17275889
Drug: Weekly cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly cisplatin and pelvic radiation (GOG 120)
Study: 17275889
Drug: Weekly cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly cisplatin and pelvic radiation (GOG 165)
Study: 11831543
Drug: lovastatin immediate-release
Normalized name: lovastatin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: lovastatin immediate-release (IR) 40 mg tablets following a standard breakfast
Study: 11831543
Drug: lovastatin extended-release
Normalized name: Lovastatin Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: lovastatin extended-release (ER) 40 mg tablets following a standard breakfast
Study: 11831543
Drug: lovastatin extended-release
Normalized name: Lovastatin Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: lovastatin extended-release (ER) 40 mg tablets under fasting conditions
Study: 11831543
Drug: lovastatin extended-release
Normalized name: Lovastatin Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: lovastatin extended-release (ER) tablets with breakfast
Study: 7728285
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (1 g/d)
Study: 2140332
Drug: Topical tetracycline
Normalized name: TETRACYCLINE HYDROCHLORIDE 30 mg in 1 mL TOPICAL SPRAY [Tetracyte Topical Tetracycline Hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tetracycline applied twice daily for 16 weeks
Study: 2140332
Drug: Placebo applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied twice daily for 16 weeks
Study: 6101956
Drug: Clorazepate dipotassium
Normalized name: Clorazepate Dipotassium
DrugBank: Clorazepic acid (DB00628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clorazepate dipotassium 5 mg
Study: 6101956
Drug: Clorazepate dipotassium
Normalized name: Clorazepate Dipotassium
DrugBank: Clorazepic acid (DB00628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clorazepate dipotassium 7.5 mg
Study: 6101956
Drug: Clorazepate dipotassium
Normalized name: Clorazepate Dipotassium
DrugBank: Clorazepic acid (DB00628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clorazepate dipotassium 15 mg
Study: 6101956
Drug: Clorazepate dipotassium
Normalized name: Clorazepate Dipotassium
DrugBank: Clorazepic acid (DB00628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clorazepate dipotassium 7.5 mg/day for 14 days
Study: 6101956
Drug: Clorazepate dipotassium
Normalized name: Clorazepate Dipotassium
DrugBank: Clorazepic acid (DB00628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clorazepate dipotassium 15 mg/day for 14 days
Study: 28100321
Drug: Esmolol treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol treatment
Study: 21331628
Drug: Functional beverage
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional beverage rich in vitamins C and E plus Lippia citriodora extract (PLX) containing 20 mg/100 ml verbascoside
Study: 19726396
Drug: Anthracycline-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracycline-based chemotherapy regimens (dose‐dense taxane, dose‐standard taxane, or dose‐standard without taxane)
Study: 17056201
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg by mouth twice per day for 2 weeks before and during CRT
Study: 17056201
Drug: Celecoxib administration
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib administration before CRT
Study: 15163253
Drug: Beaded extended-release
Normalized name: minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beaded extended-release carbamazepine capsules (ERC-CBZ; SPD417) 200-1600 mg/day, mean dose 938 mg/day
Study: 25411413
Drug: Combined dabrafenib
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Combined dabrafenib and trametinib therapy (CombiDT) at standard dose (150/2)
Study: 21698100
Drug: Acetaminophen (10-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (10-15 mg per kg)
Study: 19490462
Drug: ketamine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketamine 0.15 mg/kg i.v.
Study: 19490462
Drug: ketamine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketamine 0.15 mg/kg + midazolam 0.01 mg/kg i.v.
Study: 11392343
Drug: Amantadine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine (2.5 mg/kg per day for 1 week, then 5.0 mg/kg per day for 3 weeks)
Study: 9251847
Drug: 500 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 micrograms vaccine
Study: 2422927
Drug: Somatostatin intravenous
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin intravenous drip (250 micrograms/h) for 4 hours, started at the beginning of operation
Study: 27444119
Drug: Diet and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet and drug treatment
Study: 20542419
Drug: 10% benzocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% benzocaine gel (B10)
Study: 12569689
Drug: rhEGF ointments
Normalized name: Hu-rhEGF-rP64k/Mont
DrugBank: Hu-rhEGF-rP64k/Mont (DB15781)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhEGF ointments of 10 micrograms/g
Study: 3348613
Drug: Intravenous cefoperazone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cefoperazone (2 g) and sulbactam (1 g)
Study: 3348613
Drug: Intraperitoneal cefoperazone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal cefoperazone (2 g) and sulbactam (1 g)
Study: 31484660
Drug: DFMO (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFMO (500 mg orally) plus aspirin (325 mg)
Study: 16458629
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (conjugated estrogens, 0.625 mg, plus medroxyprogesterone acetate, 2.5 mg)
Study: 9256142
Drug: 0.075% capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.075% capsaicin cream applied to the painful site four times daily for 8 weeks
Study: 9256142
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied to the painful site four times daily for 8 weeks
Study: 8509640
Drug: Recombinant IFN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant IFN alpha‐2b alone (5 MU s.c. thrice weekly for 5 months)
Study: 8509640
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IFN alpha‐2b and recombinant IL‐2 (3 MU IFN alpha‐2b s.c. thrice weekly for 5 months, with IL-2 added starting at month 2)
Study: 26790205
Drug: Shallow-layer embedding
Normalized name: Bayer Aspirin Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shallow-layer embedding group (subcutaneous layer)
Study: 23636088
Drug: Ultrasound-guided intra-articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided intra-articular injection through midmedial portal
Study: 23636088
Drug: Ultrasound-guided intra-articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided intra-articular injection through midlateral portal
Study: 23636088
Drug: Ultrasound-guided intra-articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided intra-articular injection through superolateral portal
Study: 16855169
Drug: Etanercept (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (25 mg, twice/weekly) and Infliximab (3 mg/kg on 0, 2, 6, and every 8 weeks thereafter)
Study: 16855169
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (stable therapy with prednisone and MTX without anti-TNF-alpha therapy)
Study: 12623939
Drug: Co‐amilozide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co‐amilozide (25 mg hydrochlorothiazide and 2.5 mg amiloride) daily
Study: 11180916
Drug: Vitamin K2
Normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K2 (menatetrenone, 45 mg/day)
Study: 11180916
Drug: Calcium (calcium
Normalized name: Slow-Mag with Calcium (calcium carbonate 298 MG (calcium 119 MG) / magnesium chloride 596 MG (magnesium 71.5 MG)) Delayed Release Oral Tablet, Reformulated Feb 2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (calcium lactate, 2 g/day)
Study: 29863955
Drug: Atezolizumab plus
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab plus bevacizumab plus chemotherapy (ABCP)
Study: 17437819
Drug: Adjuvant weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant weekly docetaxel (35 mg/m² weekly for 6 cycles, starting 4 to 12 weeks post-surgery)
Study: 17437819
Drug: Adjuvant weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant weekly docetaxel
Study: 27610820
Drug: Reduced-iodine-dose dual-energy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-iodine-dose dual-energy CTA (21-27 g I)
Study: 27610820
Drug: Standard-iodine-dose single-energy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-iodine-dose single-energy CTA (30-37 g I)
Study: 24467257
Drug: Tobacco treatment
Normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobacco treatment intervention
Study: 22088576
Drug: Gentamicin 320
Normalized name: sodium citrate 4% Gentamicin 320mcg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 320 μg/mL in 4% sodium citrate
Study: 22088576
Drug: Heparin 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 1,000 U/mL
Study: 22276283
Drug: Buprenorphine (BUP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (BUP; 2 mg)
Study: 22276283
Drug: Buprenorphine (BUP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (BUP; 8 mg)
Study: 22276283
Drug: Buprenorphine/Naloxone (BUP/NX;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/Naloxone (BUP/NX; 2 mg buprenorphine + 0.5 mg naloxone)
Study: 22276283
Drug: Buprenorphine/Naloxone (BUP/NX;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/Naloxone (BUP/NX; 8 mg buprenorphine + 2 mg naloxone)
Study: 10609378
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (anticoagulants)
Study: 1789091
Drug: Soft hydrogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft hydrogel (IO-gel) lens
Study: 23344273
Drug: Immediate oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate oxytocin infusion
Study: 23344273
Drug: Delayed oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed oxytocin infusion (4 hours)
Study: 21214631
Drug: Adalimumab (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (80 mg at week 0; 40 mg every other week from weeks 1-15) with topical vehicle
Study: 21214631
Drug: Adalimumab (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (80 mg at week 0; 40 mg every other week from weeks 1-15) with topical calcipotriol/betamethasone dipropionate (C/B)
Study: 21214631
Drug: Adalimumab (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (80 mg at week 0; 40 mg every other week from weeks 1-15)
Study: 18260869
Drug: Atorvastatin (10.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10.8 +/- 0.1 mg/day)
Study: 11380321
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (metronidazole, amoxicillin, bismuth subsalicylate for 2 weeks, followed by bismuth alone for 14 weeks)
Study: 11380321
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy and calcium carbonate
Study: 9661650
Drug: Leucine 54
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine 54 (L) polymorphism
Study: 9661650
Drug: Genotype L/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype L/L
Study: 7710452
Drug: Epirubicin (EPR)
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin (EPR) 60 mg/m2 administered as an i.v. bolus over 2 min
Study: 7710452
Drug: Epirubicin (EPR)
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin (EPR) 60 mg/m2 with interferon-alpha-2b (IFN) 5 x 10(6) IU s.c. 3 times a week
Study: 28135150
Drug: High-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon α-2b at 20 MU/m2/d IV for 5 days every week for 4 weeks